Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Executive Summary

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Advertisement

Related Content

Milligan’s Retirement Means New CEO For New Gilead
Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo
Gilead Acquisition Of Cell Design: The Next Logical Step
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Sangamo Looks Forward After Shire Returns Hemophilia Rights
Juno Looks To Move CAR-T To Solid Tumors Via Editas Deal
Novartis to use gene editing tool with CAR-T therapies
Janssen touts Transposagen technology in CAR-T collaboration
Cellectis soars as Pfizer fronts $80m for immuno-oncology
BioNotebook: Sangamo/Biogen, Adamas/Forest, Zymeworks/Lilly, Sunesis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel